AR089123A1 - Suministro eficaz de lipidos a la pelicula lagrimal humana usando un sistema de emulsion sensible a sales, composicion farmaceutica oftalmica - Google Patents

Suministro eficaz de lipidos a la pelicula lagrimal humana usando un sistema de emulsion sensible a sales, composicion farmaceutica oftalmica

Info

Publication number
AR089123A1
AR089123A1 ARP120104614A ARP120104614A AR089123A1 AR 089123 A1 AR089123 A1 AR 089123A1 AR P120104614 A ARP120104614 A AR P120104614A AR P120104614 A ARP120104614 A AR P120104614A AR 089123 A1 AR089123 A1 AR 089123A1
Authority
AR
Argentina
Prior art keywords
approximately
concentration
pharmaceutical composition
ophthalmic pharmaceutical
acrylate
Prior art date
Application number
ARP120104614A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR089123A1 publication Critical patent/AR089123A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120104614A 2011-12-07 2012-12-07 Suministro eficaz de lipidos a la pelicula lagrimal humana usando un sistema de emulsion sensible a sales, composicion farmaceutica oftalmica AR089123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
AR089123A1 true AR089123A1 (es) 2014-07-30

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104614A AR089123A1 (es) 2011-12-07 2012-12-07 Suministro eficaz de lipidos a la pelicula lagrimal humana usando un sistema de emulsion sensible a sales, composicion farmaceutica oftalmica

Country Status (27)

Country Link
US (2) US20130150324A1 (enExample)
EP (5) EP3981387A1 (enExample)
JP (1) JP6142419B2 (enExample)
KR (1) KR102017922B1 (enExample)
CN (2) CN108969482A (enExample)
AR (1) AR089123A1 (enExample)
AU (2) AU2012347459A1 (enExample)
BR (1) BR112014013820A2 (enExample)
CA (1) CA2858574C (enExample)
CL (1) CL2014001518A1 (enExample)
CO (1) CO6990739A2 (enExample)
DK (2) DK2787969T3 (enExample)
ES (2) ES2797650T3 (enExample)
HU (2) HUE057140T2 (enExample)
IL (1) IL233008A (enExample)
IN (1) IN2014CN04809A (enExample)
MX (1) MX355216B (enExample)
MY (1) MY173378A (enExample)
PH (2) PH12014501296B1 (enExample)
PL (2) PL2787968T3 (enExample)
PT (2) PT2787968T (enExample)
RU (1) RU2014127074A (enExample)
SG (1) SG11201403013VA (enExample)
SI (2) SI2787969T1 (enExample)
TW (1) TWI652072B (enExample)
WO (2) WO2013086449A1 (enExample)
ZA (1) ZA201404228B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2706535T3 (es) 2016-07-07 2019-03-29 Salvat Lab Sa Composiciones oftálmicas que comprenden aceite de ricino y triglicéridos de cadena media
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
BR112020003276A2 (pt) 2017-08-18 2020-09-01 Akrivista, LLC métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano
AU2019261437B2 (en) 2018-04-27 2024-11-07 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
WO1991001718A1 (en) 1989-08-03 1991-02-21 Eisai Co., Ltd. Method of photostabilizing eyewash and photostabilized eyewash
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
AU3484895A (en) 1994-09-14 1996-03-29 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing corneal disturbance
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) * 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
KR20030023700A (ko) 2000-07-14 2003-03-19 알러간, 인코포레이티드 치료활성 성분을 함유하고 용해도가 증강된 조성물
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
EP1339418B1 (en) 2000-11-08 2009-09-23 FXS Ventures, LLC Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
JP2006504701A (ja) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
US7758883B2 (en) * 2002-10-18 2010-07-20 Aqueous Pharma Limited Three layer artificial tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
WO2004084877A1 (ja) 2003-03-26 2004-10-07 Menicon Co., Ltd. 眼科用組成物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
CN100475192C (zh) * 2003-06-13 2009-04-08 爱尔康公司 包含两种聚合物的协同组合的眼用组合物
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CN1878571B (zh) * 2003-11-10 2010-09-08 东丽株式会社 含有多糖类的组合物及泪液层稳定化滴眼剂
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
HRP20171691T1 (hr) * 2009-06-05 2017-12-15 Allergan, Inc. Umjetne suze i njihova upotreba u terapiji
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
KR102017922B1 (ko) 2019-09-03
BR112014013820A8 (pt) 2017-06-13
SI2787968T1 (sl) 2020-08-31
AU2012347459A1 (en) 2014-07-03
CA2858574C (en) 2017-05-30
US20130150324A1 (en) 2013-06-13
IL233008A (en) 2017-07-31
HK1203057A1 (en) 2015-10-16
IN2014CN04809A (enExample) 2015-09-18
WO2013086438A1 (en) 2013-06-13
PH12014501296B1 (en) 2023-04-05
MY173378A (en) 2020-01-21
CN104114152A (zh) 2014-10-22
ZA201404228B (en) 2015-12-23
PL2787968T3 (pl) 2020-08-24
ES2797650T3 (es) 2020-12-03
DK2787968T3 (da) 2020-06-02
KR20140107383A (ko) 2014-09-04
US9314528B2 (en) 2016-04-19
PL2787969T3 (pl) 2021-12-20
EP4403220A3 (en) 2024-10-23
CA2858574A1 (en) 2013-06-13
HUE049489T2 (hu) 2020-09-28
EP3666257A1 (en) 2020-06-17
RU2018119362A (ru) 2018-11-08
MX355216B (es) 2018-04-10
PH12014501296A1 (en) 2014-10-08
ES2896336T3 (es) 2022-02-24
AU2017265181B2 (en) 2019-06-20
JP2015504860A (ja) 2015-02-16
DK2787969T3 (da) 2021-11-01
SG11201403013VA (en) 2014-07-30
SI2787969T1 (sl) 2021-12-31
EP2787968B1 (en) 2020-03-04
EP2787969B1 (en) 2021-09-29
EP2787969A1 (en) 2014-10-15
MX2014006804A (es) 2014-09-22
EP4403220A2 (en) 2024-07-24
RU2018119362A3 (enExample) 2021-09-07
EP3981387A1 (en) 2022-04-13
CL2014001518A1 (es) 2014-10-24
PT2787968T (pt) 2020-06-16
US20130197083A1 (en) 2013-08-01
EP2787968A1 (en) 2014-10-15
HUE057140T2 (hu) 2022-04-28
IL233008A0 (en) 2014-07-31
PH12021553172A1 (en) 2024-05-27
CO6990739A2 (es) 2014-07-10
RU2014127074A (ru) 2016-02-10
HK1201458A1 (en) 2015-09-04
TW201325633A (zh) 2013-07-01
WO2013086449A1 (en) 2013-06-13
JP6142419B2 (ja) 2017-06-07
BR112014013820A2 (pt) 2017-06-13
AU2017265181A1 (en) 2017-12-14
TWI652072B (zh) 2019-03-01
CN108969482A (zh) 2018-12-11
PT2787969T (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
AR089123A1 (es) Suministro eficaz de lipidos a la pelicula lagrimal humana usando un sistema de emulsion sensible a sales, composicion farmaceutica oftalmica
ES2537539T3 (es) Composición oftálmica
AR081232A1 (es) Bomba para fluido oftalmico
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
CL2014000863A1 (es) Una composicion oftalmologica que comprende monooleato de polioxietileno (80) sorbitan, carboximetilcelulosa sodica, glicerina, acido borico, polimero reticulado de acrilatos/acrilato de alquilo c10-30, aceite de ricino, eritritol, levocarnitina, hidroxido de sodio y agua; y su uso para tratar, mitigar o prevenir el sindrome del ojo seco.
BR112014009129A2 (pt) sistema e método para exibição holográfica interativa
AR100334A1 (es) Solución oftálmica acuosa y método para tratar el síndrome del ojo seco
BR112016010103A8 (pt) métodos, kits e dispositivos de suprimento de fármaco osmótico.
AR096975A1 (es) Formulación líquida en aerosol de un artículo electrónico para fumar
BR112017024157A2 (pt) aparelho, sistema e método de determinação de uma distância pupilar
AR097791A1 (es) Formulaciones de anticuerpos anti-pdl1
BR112015032985A2 (pt) Sistema de distribuição de fragrância, dispositivo de distribuição de fragrância e método para operar um sistema de distribuição de fragrância
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2015006632A (es) Formulaciones de uso topico de tetraciclina, preparaciones y usos de las mismas.
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
CL2015001852A1 (es) Películas de ésteres de poli alfa-1, 3-glucano y metodo para su preparación
AR096773A1 (es) Formulación líquida estable
MX2015012134A (es) Forma de dosificacion de dispersion rapida que contiene levetiracetam.
PE20150083A1 (es) Formulacion de ibuprofeno inyectable
BRPI1106763B8 (pt) Dispositivo e sistema de processamento de informação para participar em uma sessão de aplicativo, e, mídia de gravação não transitória legível por computador
CO6280502A2 (es) Una composicion farmaceutica
PE20170646A1 (es) Sistema de evaluacion de riesgos para sistema de proceso, programa de evaluacion de riesgos y metodos de evaluacion de riesgos
BR112016002763A2 (pt) aparelho para processamento de informação e método para fornecer resultado de determinação
BR112015026809A8 (pt) Sistema e método para fornecer uma lente oftálmica
MX2017004972A (es) Indicador de humedad quimioluminiscente para productos absorbentes.

Legal Events

Date Code Title Description
FC Refusal